Document is current
Any future updates will be listed below
-
Authors
Dunca, Diana https://orcid.org/0009-0007-7461-7520
Chopade, Sandesh
Gordillo-Marañón, María https://orcid.org/0000-0003-2993-6577
Hingorani, Aroon D. https://orcid.org/0000-0001-8365-0081
Kuchenbaecker, Karoline https://orcid.org/0000-0001-9726-603X
Finan, Chris https://orcid.org/0000-0002-3319-1937
Schmidt, Amand F. https://orcid.org/0000-0003-1327-0424
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MR/NO13867/1)
- License Information
-
More Information
Article History
Received: 19 July 2023
Accepted: 24 May 2024
First Online: 21 June 2024
Competing interests
: AFS and CF have received unrestricted funding from New Amsterdam Pharma, which is currently developing the CETP-inhibitor obicetrapib. The views expressed in this study are the personal views of MGM and do not represent the views of her current employer, the European Medicines Agency. All the authors declare no other competing interests.
